Krishnansu Tewari

Professor & Interim Division Director, Obstetrics & Gynecology
School of Medicine

M.D., University of California, Irvine, 1994

Phone: (714) 456-8020
Email: ktewari@uci.edu

University of California, Irvine
333 City Blvd. West
Suite 1400
Orange, CA 92868

picture of Krishnansu  Tewari

   
Appointments 2012 – present
Professor with Tenure
Department of Obstetrics and Gynecology
Division of Gynecologic Oncology
University of California, Irvine Medical Center

2006 – 2012
Associate Professor of Clinical X
Department of Obstetrics and Gynecology
Division of Gynecologic Oncology
University of California, Irvine Medical Center

2002-2006
Assistant Clinical Professor
Volunteer Faculty - Department of Obstetrics & Gynecology
University of California, Irvine Medical Center

1998-2002
Clinical Instructor
Fellow – The Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
University of California, Irvine Medical Center

NON-ACADEMIC APPOINTMENTS

2011-present
Director, Gynecologic Oncology Program
Center for Cancer Prevention & Treatment
St. Joseph’s Medical Center
Orange, CA

2002-2006
Gynecologic Oncologist
Kaiser Foundation Hospitals
Riverside, Baldwin Park, Bellflower and Harbor City, CA
   
Publications BOOK CHAPTERS

1. Tewari KS. Vulvar neoplasia. In: Cancer Diagnosis and Early Prevention in Women, Manetta A (ed). Mosby Publication, 2003.

2. Tewari KS. The adventure of the three abnormal Paps. In: The Best of After Office Hours, Pitkin RM, Rinehart RD (eds). The American College of Obstetrics & Gynecology, 2003.

3. Berman ML, DiSaia PJ and Tewari KS. Pelvic malignancies, Gestational Trophoblastic Neoplasia, and Nonpelvic malignancies. Chapter 58, pp.1213-1242. In: Maternal-Fetal Medicine: Principles and Practice, Ed 5, Creasy RK, Resnik R (eds). Saunders, Philadelphia, Pennsylvania, 2004.

4. Tewari KS, Berman ML. Cytoreductive Surgery in the Left Upper Abdomen. In: Surgery for Ovarian Cancer: Principles and Practice. Bristow RE, Karlan BY (eds), Taylor & Francis, 2005.

5. Tewari KS, Monk BJ. Tumors of the Cervix. In: Textbook of Uncommon Cancers, Ed 3, Raghaven D, Brecher ML, Johnson DH, Meropol NJ, Moots PL, Rose PG, Mayer IA (eds). Wiley, 2006.

6. Tewari KS. Cancer in Pregnancy. In: Clinical Gynecologic Oncology, 7th Ed, DiSaia PJ, Creasman WT (eds) Mosby Elsevier, 2007.

7. Monk BJ, Tewari KS. Invasive Cervical Cancer. In: Clinical Gynecologic Oncology, 7th Ed, DiSaia PJ, Creasman WT (eds) 2007, Mosby Elsevier, 2007.

8. Tewari KS, Berman ML. A Brief History of Gynecologic Oncology in the United States. In: Fellows’ Handbook of Gynecologic Oncology. Chapter 43, European Society of Gynecologic Oncology, 1st Ed, Ayhan A, Gultekin, M (eds), 2009.

9. Monk BJ, Tewari KS. The Spectrum and Clinical Sequelae of Human Papillomavirus Infection. In: Fellows’ Handbook of Gynecologic Oncology. Chapter 72, European Society of Gynecologic Oncology, 1st Ed, Ayhan A, Gultekin, M (eds), 2009.

10. Martinez A, Tewari KS, Ferron G, Ramirez PT. Cytoreductive Surgery: Upper Abdomen – Left Hypochondriac and Epigastric Regions. In: Surgery for Ovarian Cancer: Principles and Practice. 2nd Edition. Bristow RE, Karlan BY, Chi DS (eds), Informa Healthcare, 2010.

11. Tewari KS. Cancer in Pregnancy. In: DiSaia & Creasman’s Clinical Gynecologic Oncology, 8th Ed, McMeekin SD, Mutch (eds), 2011.

12. Tewari KS, Monk BJ. Invasive Cervical Cancer. In: DiSaia & Creasman’s Clinical Gynecologic Oncology, 8th Ed, McMeekin SD, Mutch (eds), 2011.

13. Tewari KS, Brewster WR. Clinical Trials. In: Surgical Atlas of Gynecologic Oncology, 1st Ed, Bristow RE, Karlan BY (eds), 2011.

14. Tewari KS. Neoplasia in Pregnancy. In: University of California, Obstetrics & Gynecology, Women’s Health Review. DiSaia PJ (ed), 2011.

15. Tewari KS, Monk BJ. Invasive Cervical Cancer. In: University of California, Obstetrics & Gynecology, Women’s Health Review. DiSaia PJ (ed), 2011.

16. Tewari KS, Berman ML. A Brief History of Gynecologic Oncology in the United States. In: Fellows’ Handbook of Gynecologic Oncology. Chapter 43, European Society of Gynecologic Oncology, 2nd Ed, Ayhan A, Gultekin, M (eds), 2011.

17. Tewari KS, Monk BJ. The Spectrum and Clinical Sequelae of Human Papillomavirus Infection. In: Fellows’ Handbook of Gynecologic Oncology. Chapter 72, European Society of Gynecologic Oncology, 2nd Ed, Ayhan A, Gultekin, M (eds), 2011.

18. Tewari KS, Monk BJ. Tumors of the Cervix. In: Textbook of Uncommon Cancers, Ed 4, Raghaven D, Brecher ML, Johnson DH, Meropol NJ, Moots PL, Rose PG, Mayer IA (eds). Wiley, 2011.

19. Tewari KS. History of radical pelvic surgery. Radical Pelvic Surgery in Gynecologic Oncology. Bristow RE (ed), Elsevier (in production).

20. Tewari KS, Monk BJ. 21st Century Clinical Ovarian Cancer. Springer Healthcare LLC (in production).

21. Tewari KS, Monk BJ. 21st Century Clinical Cervical Cancer. Springer Healthcare LLC (in development).

22. Tewari KS. History of ovarian cancer surgery. In: Surgery for Ovarian Cancer: Principles and Practice, 3rd edition. Bristow RE, Karlan BY, Chi D (eds).

23. Tewari KS. Etiology and pathogenesis of cervical cancer. Chapter 2.2. In: @POC Gynecologic Cancer: Ovarian and Cervical Cancers. Tewari KS (ed).

24. Tewari KS. Screening and prevention of cervical cancer. Chapter 3.2. In: @POC Gynecologic Cancer: Ovarian and Cervical Cancers. Tewari KS (ed).

25. Tewari KS. Case study in cervical cancer. In: @POC Gynecologic Cancer: Ovarian and Cervical Cancers. Tewari KS (ed).

26. Tewari KS, Burger RA. Handbook on targeted therapy in gynecologic malignancies. (in development)

27. Tewari KS, Penson RT, Monk BJ. Tumors of the Ovary and Fallopian Tube. In: Principles and Practices of Oncology, 11th ed. DeVita (ed). (in development)

JOURNAL ARTICLES, PEER REVIEWED

1. Monk BJ, Walker JL, Tewari K, Ramsinghani NS, Syed AMN and DiSaia PJ. Open interstitial brachytherapy for the treatment of local-regional recurrences of uterine corpus and cervix cancer after primary surgery. Gynecol Oncol 1994;52:222-8.

2. Monk BJ, Tewari K, Gamboa-Vujicic G, Burger RA, Manetta A and Berman ML. Does perioperative blood transfusion affect survival in patients with cervical cancer treated with radical hysterectomy? Obstet Gynecol 1995;85:343-8.

3. Tewari K, Steiger RM, Monk BJ, Scannell G, Tominaga G and Waxman K. Should critical care medicine be a formal part of the undergraduate curriculum? J Intensive Care Med 1996;11:13-8.

4. Tewari K, Wold SM and Asrat T. Septic shock in pregnancy associated with legionella pneumonia. Am J Obstet Gynecol 1997;176:706-7.

5. Manetta A, Tewari K and Podczaski ES. Hexamethylmelamine as a single second-line agent in ovarian cancer: Follow-up report and review of the literature. Gynecol Oncol 1997;66:20-6.

6. Cappuccini F, Tewari K, Rogers LW and DiSaia PJ. Extramammary Paget’s disease of the vulva: Metastases to the bone marrow in the absence of an underlying adenocarcinoma – Case report and literature review. Gynecol Oncol 1997;66:146-50.

7. Tewari K, Bonebrake RG, Asrat T and Shanberg AM. Ambiguous genitalia in infant exposed to tamoxifen in utero secondary to inflammatory breast cancer during pregnancy. Lancet 1997;350:183.

8. Tewari K, Brewer C, Cappuccini F, Macri C, Rogers LW and Berman ML. Advanced stage small cell carcinoma of the ovary in pregnancy: Long-term survival after surgical debulking and multi-agent chemotherapy. Gynecol Oncol 1997;66:531-4.

9. Monk BJ, Tewari K, Burger RA, Johnson MT, Montz FJ and Berman ML. A comparison of intracavitary versus interstitial irradiation in the treatment of cervical cancer. Gynecol Oncol 1997;67:241-7.

10. Tewari K, Rose GS, Balderston KD, Porto M and Kohler MF. Fertility drugs and malignant germ cell tumour of the ovary in pregnancy. Lancet 1998;351:957-8.

11. Tewari K, Cappuccini F, Gambino A, Kohler MF, Pecorelli S and DiSaia PJ. Neoadjuvant chemotherapy in the management of locally advanced cervical carcinoma in pregnancy: A report of two cases and review of issues specific to the management of cervical cancer in pregnancy, including, planned delay of therapy. Cancer 1998;82:1529-34.

12. Tio I, Tewari K, Balderston KD, Milliken JC and Porto M. Emergency mitral valve replacement in the setting of severe pulmonary hypertension and acute cardiovascular decompensation following evacuation of twins at fifteen weeks’ gestation. Am J Obstet Gynecol 1998;179:270-2.

13. Cappuccini F, Tewari K, Fuller PN, Pindur A and DiSaia PJ. Aggressive clinical behavior of a rare uterine sarcoma. Gynecol Oncol 1998;70:147-51.

14. Tewari K, Balderston KD, Carpenter SE and Major CA. Papillary thyroid carcinoma manifesting as a thyroid storm in pregnancy. Am J Obstet Gynecol 1998;179:818-9.

15. Balderston KD, Tewari K, Azizi F and Yu JK. Intrahepatic cholangiocarcinoma masquerading as the syndrome of hemolysis, elevated liver enzymes and low platelets of pregnancy. Am J Obstet Gynecol 1998;179:823-4.

16. Balderston KD, Tewari K, Gregory WT, Berman ML and Kucera PR. Neuroendocrine small cell carcinoma of the uterine cervix in pregnancy: Long-term survival following combined therapy. Gynecol Oncol 1998;71:128-32.

17. Tewari K, Cappuccini F, Balderston KD, Rose GS, Porto M and Berman ML. Pregnancy in a Jehovah’s Witness with cervical cancer and anemia. Gynecol Oncol 1998;71:330-2.

18. Taylor JA, Tewari K, Liao SY, Hughes CCW and Villarreal LP. Immunohistochemical analysis, human papillomavirus DNA detection, hormonal manipulation and exogenous gene expression of normal and dysplastic human cervical epithelium in severe combined immunodeficiency mice. J Virol 1999;73:5144-8.

19. Moore MM, Tewari K, Rose GS, Freuhauf JP and DiSaia PJ. Long-term consequences following conservative management of epithelial ovarian cancer in an infertile patient. Gynecol Oncol 1999;73:452-4.

20. Tewari K, Cappuccini F, Syed AMN, Puthawala AA, DiSaia PJ, Berman ML, Manetta A and Monk BJ. Interstitial brachytherapy in the treatment of locally advanced and recurrent vulvar cancer. Am J Obstet Gynecol 1999;181:91-8.

21. Tewari K, Cappuccini F, Rosen RB, Rosenthal J, Asrat T and Kohler MF. Relapse of acute lymphoblastic leukemia in pregnancy: Survival following chemoirradiation and autologous transfer of interleukin-2 activated stem cells. Gynecol Oncol 1999;74:143-6.

22. Tewari K, Cappuccini F, Brewster WR, DiSaia PJ, Berman ML, Manetta A, Puthawala AA, Syed AMN and Kohler MF. Interstitial brachytherapy for vaginal recurrences of endometrial cancer. Gynecol Oncol 1999;74:416-22.

23. Tewari K, Asrat T, Ruttgers JKL and Nageotte MP. The evolution of linitis plastica as a consequence of advanced gastric carcinoma in pregnancy. Am J Obstet Gynecol 1999;181:757-8.

24. Tewari K and DiSaia PJ. Authors’ reply to “Comment on: Neoadjuvant chemotherapy for the management of locally advanced cervical carcinoma in pregnancy.” (Letter) Cancer 1999;85:1203-4.

25. Tewari K and Manetta A. In vitro chemosensitivity testing and mechanisms of drug resistance in epithelial ovarian cancer. Curr Oncol Rep 1999;1:77-84.

26. Tewari K, Cappuccini F, DiSaia PJ, Berman ML, Manetta A and Kohler MF. Malignant germ cell tumors of the ovary. Obstet Gynecol 2000;95:128-33.

27. Tewari KS, Taylor JA, Liao SY, DiSaia PJ, Burger RA, Monk BJ, Hughes CCW and Villarreal LP. Development and assessement of a general theory of cervical carcinogenesis utilizing a severe combined immunodeficiency murine-human xenograft model. Gynecol Oncol 2000;77:137-48.

28. Tewari KS, Cappuccini F, Asrat T, Flamm BL, Carpenter SE, DiSaia PJ and Quilligan EJ. Obstetrical emergencies precipitated by malignant brain tumors. Am J Obstet Gynecol 2000;182:1215-21.

29. Tewari KS, Kyshtoobayeva AS, Mehta RS, Yu I-R, Burger RA, DiSaia PJ and Fruehauf JP. Biomarker conservation in primary and metastatic epithelial ovarian cancer. Gynecol Oncol 2000;78:130-6.

30. Tewari KS. The adventure of the three abnormal PAPs. Obstet Gynecol 2000;96:795-8.

31. Tewari KS and DiSaia PJ. On the evolution of a successful treatment program for a solid tumour system. Eur J Gynaecol Oncol 2000;21:339-47.

32. Tewari KS, Cappuccini F, Puthawala AA, Kuo JV, Burger RA, Monk BJ, Manetta A, Berman ML, DiSaia PJ and Syed AMN. Primary invasive carcinoma of the vagina: Treatment with interstitial brachytherapy. Cancer 2001;91:758-70.

33. Tewari KS, Steiger RM, Lam MM, Ruttgers JKL, Berkson RA and DiSaia PJ. Bilateral pheochromocytomas in pregnancy heralding multiple endocrine neoplasia syndrome IIA. J Reprod Med J Reprod Med. 2001;46:385-8.

34. Chan JK, Lin YG, Monk BJ, Tewari K, Bloss JD and Berman ML. Vaginal hysterectomy as primary treatment of endometrial cancer in medically compromised women. Obstet Gynecol 2001;97:707-111.

35. DiSaia PJ and Tewari KS. Recent advancements in the treatment of epithelial ovarian cancer. J Obstet Gynaecol Res 2001;27:61-75.

36. Naylor CS, Tewari K and Asrat T. Trisomy 13 in one fetus from a twin gestation after intracytoplasmic sperm injection. J Reprod Med 2001 46:497-8.

37. Tewari KS and DiSaia PJ. Radiation therapy for gynecologic cancer. J Obstet Gynaecol Res 2002;28:123-40.

38. Tewari KS and DiSaia PJ. Lung and bronchus cancer in women: A 21st Century epidemic. Clin Obstet Gynecol 2002;45:784-811.

39. Monk BJ, Tewari KS, Puthawala AA, Syed AMN, Haugen JA, Burger RA. Treatment of recurrent gynecologic malignancies with iodine-125 permanent interstitial irradiation. Int J Radiat Oncol Biol Phys 2002;52:806-15.

40. Tewari KS and DiSaia PJ. Primary prevention of uterine cervix cancer: Focus on vaccine history and current strategy. Obstet Gynecol Clin North Am 2002 29:843-68.

41. Syed AMN, Puthawala AA, Abdelaziz NN, el-Naggar M, DiSaia PJ, Berman ML, Tewari KS, Sharma A, Londre A, Juwadi S, Cherlow JM, Damore S and Chen YJ. Long-term results of low-dose-rate interstitial-intracavitary brachytherapy in the treatment of carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2002;54:67-78.

42. Berg JC, Tewari KS, Del Rosario R and Berman ML. Unusual presentation of a malignant granular cell tumor of the pelvis: Case report and literature review. Gynecol Oncol 2003;90:224-30.

43. Geas FL, Tewari DS, Rutgers JKL, Tewari KS and Berman ML. Surgical cytoreduction and hormonal therapy of an advanced endometrioid stromal sarcoma of the ovary. Obstet Gynecol 2004;103:1051-4.

44. Tewari KS, Mehta RS, Burger RA, Kyshtoobayeva AS, Yu I-R, Monk BJ, Manetta A, Berman ML, DiSaia PJ and Fruehauf JP. Conservation of in vitro drug resistance patterns in epithelial ovarian cancer. Gynecologic Oncology, 2005;98:360-8.

45. Tewari KS, Monk BJ. Gynecologic Oncology Group trials of chemotherapy for metastatic and recurrent cervical carcinoma. Curr Oncol Rep, 2005;7:419-34.

46. Tewari KS, DiSaia PJ. Ovulatory failure, fertility preservation and reproductive strategies in the setting of gynecologic and non-gynecologic malignancies. Eur J Gynaecol Oncol 2006;27:449-61.

47. Monk BJ, Tewari KS, Koh W-J. Multimodality therapy for locally advanced cervical carcinoma: State of the art and future directions. J Clin Oncol 2007; 25:2952-65.

48. Monk BJ, Tewari KS. The spectrum and clinical sequelae of human papillomavirus infection. Gynecol Oncol 2007;107:S6-13.

49. Chan JK, Tewari KS, Waller S, Cheung MK, Shin JY, Osann K, Kapp DS. The influence of conservative surgical practices for malignant ovarian germ cell tumors. J Surg Oncol 2008;98:111-6.

50. Chase DM, Monk BJ, Wenzel LB, Tewari KS. Supportive care for women with gynecologic cancers. Expert Rev Anticancer Ther 2008;8:227-41.

51. Hunter MI, Monk BJ, Tewari KS. Cervical neoplasia in pregnancy. Part 1: Screening and management of preinvasive disease. 2008;199:3-9.

52. Hunter MI, Tewari K, Monk BJ. Cervical neoplasia in pregnancy. Part 2: Current treatment of invasive disease. Am J Obstet Gynecol 2008;199:10-8.

53. Meltzer S, Monk BJ, Tewari KS. Green tea catechins in the treatment of external genital warts. Am J Obstet Gynecol 2009;200:233.e1-7. Epub 2008 Nov 18.

54. Monk BJ, Tewari KS. Sentinel lymph node dissection in vulvar carcinoma: What is the acceptable false-negative rate? Oncologist 2008;22:538-42.

55. Gatcliffe TA, Tewari KS, Shah A, Brewster WR, Burger RA, Kuo JV, Monk BJ. A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer. Gynecol Oncol 2009;112:85-9.

56. Tewari KS, Monk BJ. Recent achievements and future developments in advanced and recurrent cervical cancer: Trials of the Gynecologic Oncology Group. Semin Oncol 2009;36:170-80.

57. Mahdavi A, Monk BJ, Ragazzo J, Hunter MI, Lentz SE, Vasilev SA, Tewari KS. Pelvic radiation improves local control after hysterectomy for uterine leiomyosarcoma: A 20-year experience. Int J Gynecol Cancer 2009;19:1080-4.

58. Tewari KS, Monk BJ. Beyond platinum for metastatic and recurrent carcinoma of the cervix. Onkologie 2009;32:552-4.

59. Chase DM, Rincon A, Deane M, Tewari KS, Brewster WR. Socioeconomic factors may contribute to neoadjuvant chemotherapy use in metastatic epithelial ovarian carcinoma. Gynecol Oncol 2009;115:339-42.

60. Kalantari M, Chase DM, Tewari KS, Bernard H-U. Recombination of human papillomavirus-16 and host DNA in exfoliated cervical cells: A pilot study of L1 gene methylation and chromosomal integration as biomarkers of carcinogenic progression.. J Med Virology 2010;82:311-20.

61. Tewari KS. A critical need for reappraisal of therapeutic options for women with metastatic and recurrent cervical carcinoma: Commentary on Gynecologic Oncology Group protocol 204. Am J Hematol Oncol 2010;9:31-4.

62. Tewari KS. Patients with metastatic/recurrent cervical cancer should be treated with cisplatin plus paclitaxel. Expert Panel. Clin Ovarian Cancer 2011;4:90-3.

63. Tewari KS, Monk BJ. The rationale for the use of non-platinum chemotherapy doublets for metastatic and recurrent cervical carcinoma. Clin Adv Hematol Oncol 2010;8:108-15.

64. Chase DM, Mathur N, Tewari KS. Drug discovery in ovarian cancer. Recent Pat Anticancer Drug Discov 2010;5:251-60.

65. Hurteau JA, Brady MF, Darcy KM, McGuire WP, Edmonds P, Pearl ML, Ivanov I, Tewari KS, Mannel RS, Zanotti K, Benbrook DM. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube, or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group study. Gynecol Oncol 2010;119:444-50.

66. Eskander RN, Randall LM, Berman ML, Tewari KS, DiSaia PJ, Bristow RE. Fertility preserving options in patients with gynecologic malignancies. Am J Obstet Gynecol 2011;205:103-10.

67. Schilder RJ, Blessing JA, Shahin MS, Miller DS, Tewari KS, Miller CY, Warshal DP, McMeekin S, Rotmensch J. A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group trial. Int J Gynecol Cancer 2010;20:1137-41.

68. Tewari KS, Monk BJ. American Society of Clinical Oncology 2011 Annual Meeting update. Summary of selected gynecologic cancer abstracts. Gynecol Oncol 2011;122:209-12.

69. Tewari KS, Filiaci VL, Spirtos NM, Mannel RS, Thigpen JT, Cibull ML, Monk BJ, Randall ME. Association of number of positive nodes and cervical stromal invasion with outcome of advanced endometrial cancer treated with chemotherapy or whole abdominal irradiation: A Gynecologic Oncology Group study. Gynecol Oncol 2012 125:87-93. Epub 2011 Dec 8.

70. Dellinger TH, Planutis K, Tewari KS, Holcombe RF. Role of canonical Wnt signaling in endometrial carcinogenesis. Expert Rev Anticancer Ther 2012;12:51-62.

71. Eskander RN, Tewari KS. Emerging treatment options for management of malignant ascites in patients with ovarian cancer. Int J Women’s Health 2012;4:395-404.

72. Eskander RN, Tewari KS. Impact of chemotherapy-induced neutropenia on survival in patients with breast, ovarian, and cervical cancer: A systematic review. J Hematol Malig 2012;2:63-73.

73. Chase DM, Osann K, Sepina N, Wenzel L, Tewari KS. The challenge of follow-up in a low-income colposcopy clinic: Characteristics associated with noncompliance in high-risk populations. J Low Genit Tract Dis 2012;16:345-51.

74. Leslie KK, Sill MW, Lankes HA, Fischer EG, Godwin AK, Gray H, Schilder RJ, Walker JL, Tewari K, Hanjani P, Abulafia O, Rose PG. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecol Oncol 2012;127:345-50.

75. Tewari KS. Advanced cytoreductive surgery workshop report. Int J Gynecol Cancer 2012;22:1604-10.

76. Tewari KS. American Society of Clinical Oncology 2012 Annual Meeting: Highlights from the Gynecologic Oncology Track. Int J Gynecol Cancer 2012;22:1634-9.

77. Pinn-Bingham M, Puthawala AA, Syed AM, Sharma A, DiSaia PJ, Berman ML, Tewari KS, Randall-Whitis L, Mahmood U, Ramsinghani N, Kuo J, Chen WP, McLaren CE. Outcomes of high-dose-rate interstitial brachytherapy in the treatment of locally advanced cervical cancer: Long-term results. Int J Radiat Oncol Biol Phys 2013;85:714-20.

78. Eskander RN, Baruah J, Nayak R, Brueseke T, Ji T, Wardeh R, Tewari KS. Outside slide review in Gynecologic Oncology: Impact on patient care and treatment. In J Gynecol Pathol 2013;32:293-8.

79. Leslie KK, Sill MW, Fischer E, Darcy KM, Mannel RS, Tewari KS, Hanjani P, Wilken JA, Baron AT, Godwin AK, Schilder RJ, Singh M, Maihle NJ. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: A Gynecolgoic Oncology Group study. Gynecol Oncol 2013;129:486-94.

80. Brueseke TJ, Tewari KS. Toll-like receptor 8: Augmentation of innate immunity in platinum resistant ovarian carcinoma. Clin Pharmacol 2013;5:13-9.

81. Bristow RE, Hodeib M, Smith A, Chan DW, Zhang Z, Fung ET, Tewari KS, Munrose DG, Ueland FR. Impact of a multivariate index assay on referral patterns for surgical management of an adnexal mass. Am J Obstet Gynecol 2013;209:581.e1-8.

82. Eskander RN, Tewari KS. Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer. Clin Pharmacol 2013;5(Suppl 1):55-61.

83. Liu FW, Randall LM, Tewari KS, Bristow RE. Racial disparities and patterns of ovarian cancer surgical care in California. Gynecol Oncol 2014;132:221-6.

84. DiSilvestro P, Ali S, Craighead PS, Lucci JA, Lee YC, Cohn DE, Spirtos NM, Tewari KS, Muller C, Gajewski WH, Steinhoff MM, Monk BJ. Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: A Gynecologic Oncology Group study. J Clin Oncol 2014;32:458-64.

85. Eskander RN, Tewari KS. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma – Mechanistics, review of phase III randomized clinical trials, and regulatory implications. Gynecol Oncol 2014;132:496-505.

86. Kalantari M, Osann K, Calleja-Macias IE, Kim S, Yan B, Jordan S, Chase DM, Tewari KS, Bernard HU. Methylation of human papillomavirus 16, 18, 31, 45 L2 and L1 genes and the cellular DAPK gene: Considerations for use as biomarkers of the progression of cervical neoplasia. Virology 2014;448:314-21.

87. EskanderRN, Tewari KS. American Society of Clinical Oncology 2013: Summary of scientific achievements in gynecologic cancer. Int J Gynecol Cancer 2014;24:13-8.

88. Tewari KS, Sill MW, Long III HJ, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, Monk BJ. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014;370:34-43.

89. Tewari KS. New world order(s): Healthcare metrics, international borders, and gravitational waves. Gynecol Oncol 2014;133:139-41.

90. Tewari KS, Java JJ, Gatcliffe TA, Bookman MA, Monk BJ. Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: An exploratory study of the Gynecologic Oncology Group. Gynecol Oncol 2014;133:439-45.

91. Eskander RN, Osann K, Dickson E, Holman L, Rauh-Hain A, Spoozak L, Wu E, Krill L, Fader AN, Tewari KS. Assessment of palliative care training in Gynecologic Oncology: A A Gynecologic Oncology Fellow Research Network Study. Gynecol Oncol 2014;134:379-84.

92. Eskander RN, Tewari KS. PARP inhibition and synthetic lethality in ovarian cancer. Expert Rev Clin Pharmacol 2014;7:613-22.

93. Eskander RN, Tewari KS. Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer. Curr Opin Obstet Gynecol 2014;26:314-21.

94. Eskander RN, Tewari KS. Beyond angiogenesis blockade: Targeted therapy for advanced cervical cancer. J Gynecol Oncol 2014; 25:249-59.

95. Long B, Eskander RN, Tewari KS. The use of stereotactic radiosurgery in the treatment of gynecologic malignancies: A Review. World J Radiol 2014;6:366-73.

96. Miller DS, Blessing JA, Ramondetta LM, Pham HT, Tewari KS, Landrum LM, Brown J, Mannel RS. Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: A limited access phase II trial of the Gynecologic Oncology Group.. J Clin Oncol 2014;32:2744-9.

97. Monk BJ, Tewari KS. Evidence-based therapy for recurrent cervical cancer. J Clin Oncol 2014;32:2687-90.

98. Eskander RN, Tewari KS. Targeting angiogenesis in advanced cervical cancer. Ther Adv Med Oncol 2014;6:280-92.

99. Sherman ME, Piedmonte M, Mai PL, Ioffe OB, Ronnett BM, Van Le L, Iouri Ivanov, Bell MC, Blank SV, DiSilvestro P, Hamilton CA, Tewari KS, Wakeley K, Kauff ND, Yamada SD, Rodriguez G, Skates SL, Alberts DS, Walker JL, Minasian L, Lu K, Greene MH. Pathologic findings in risk-reducing salpino-oophorectomy (RRSO): Primary results from Gynecologic Oncology Group Trial GOG-0199. J Clin Oncol 2014;32:3275-83.

100. Tewari KS, Tracy L, DiSaia PJ. Full-thickness skin grafts for neovaginal construction in Mayer-Rokitansky-Kuster-Hauser syndrome. Description of surgical technique and early results. J Gynecol Surg 2015;31:52-7.

101. Tewari KS, Monk BJ. New strategies in advanced cervical cancer: From angiogenesis blockade to immunotherapy. Clin Cancer Res 2014;20:5349-58.

102. Eskander RN, Tewari KS. Exploiting the PI3K-AKT-mTOR pathway in enriched populations of gynecologic malignancies. Expert Rev Clin Pharmacol 2014;7:847-58.

103. Tewari KS, Monk BJ. Development of a platform for systemic anti-angiogenesis therapy for advanced cervical cancer. Clin Adv Hematol Oncol 2014;12:737-48.

104. Gibson SJ, Tewari KS, Monk BJ, Chase DM. Updates on drug discovery in ovarian cancer. Gynecol Oncol Res Pract 2014; Sept 30.

105. Eskander RN, Tewari KS. Development of bevacizumab in advanced cervical cancer: Pharmacohynamic modeling, survival impact, and toxicology. Future Oncol 2015;11:909-22.

106. Krill L, Tewari KS. Exploring the therapeutic rationale for angiogenesis blockade in cervical cancer. Clin Ther 2015;37:9-19.

107. Eskander RN, Tewari KS. Immunotherapy: An evolving paradigm in the treatment of advanced cervical cancer. Clin Ther 2015;37:20-38.

108. Long BJ, Chang J, Ziogas A, Tewari KS, Anton-Culver H, Bristow RE. Impact of race, socioeconomic status, and the healthcare system on the treatment of advanced stage ovarian cancer in California. Am J Obstet Gynecol 2015;212:468.e1-9.

109. Krill L, Tewari KS. Integration of bevacizumab with chemotherapy doublets for advanced cervical cancer. Expert Opin Pharmacother 2015;16:675-83.

110. Penson RT, Huang HQ, Wenzel LB, Monk BJ, Stockman S, Sill MW, Long III HJ, Ramondetta LM, Landrum LM, Oaknin A, Reid TJA, Leitao MM, Michael HE, Tewari KS. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase III trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncol 2015;16:301-11.

111. Minion LE, Bai J, Monk BJ, Keller RL, Eskander RN, Forde GK, Chan JK, Tewari KS. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecol Oncol 2015;137:490-6.

112. Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation – An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 2015;137:386-91.

113. Forde GK, Chang J, Ziogas A, Tewari K, Bristow RE. Costs of treatment of elderly women with advanced ovarian cancer in a Medicare population. Gynecol Oncol 2015;137:479-84.

114. Cripe J, Eskander RN, Tewari KS. Sentinel lymph node mapping of a breast cancer of the vulva: Case report and literature review. World J Clin Oncol 2015;6:16-21.

115. Eskander RN, Lynch HT, Brown SM, Wagman LD, Tewari KS. Novel MSH2 mutation in the first report of a Vietnamese American kindred with Lynch Syndrome. Gynecol Oncol Rep 2015;12:31-3.

116. Liu FW, Cripe J, Tewari KS. Antiangiogenesis therapy in gynecologic malignancies. Oncology 2015;29:350-60.

117. Wolford JE, Tewari KS. US FDA Oncology Drug Approvals in 2014. Future Oncol 2015;22:1-15.

118. Tewari KS, Eskander RN, Monk BJ. Development of olaparib for BRCA deficient recurrent epithelial ovarian cancer. Clin Cancer Res 2015;21:3829-35.

119. Pfaendler KS, Tewari KS. Changing paradigms in the systemic treatment of advanced cervical cancer. Am J Obstet Gynecol 2016;214:22-30.

120. Tewari KS. Clinical implications of cediranib in advanced cervical cancer. Lancet Oncol 2015;16:1447-8.

121. Longoria TC, Tewari KS. Pharmacologic management of advanced cervical cancer: Antiangiogenesis therapy and immunotherapeutic considerations. Drugs 2015;75:1853-65.

122. Tewari KS, Java JJ, Eskander RN, Monk BJ, Burger RA. Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Ann Oncol 2016;27:114-21.

123. Hodeib M, Serna-Gallegos T, Tewari KS. A review of HER2-targeted therapy in breast and ovarian cancer: lessons from antiquity – CLEOPATRA and PENELOPE. Future Oncol 2015;11:3113-31.

124. Tewari KS, Sill MW, Monk BJ, Penson RT, Long HJ 3rd, Poveda A, Landrum LM, Leitao MM, Brown J, Reid TJ, Michael HE, Moore DH. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemothehrapy with/without bevacizumab: NRG Oncology/GOG study. Clin Cancer Res 2015;21:5480-7.

125. Alldredge JK, Tewari KS. Clinical trials of anti-angiogenesis therapy in recurrent/persistent and metastatic cervical cancer. Oncologist 2016; 21:576-85.

126. Liu FW, Tewari KS. New targeted agents in gynecologic cancers: Synthetic lethality, homologous recombination deficiency, and PARP inhibitors. Curr Treat Options Oncol 2016;17:12.

127. LaFargue CJ, Tewari KS. Recent patents for homologous recombination deficiency assays among women with ovarian cancer. Recent Pat Biotechnol 2016;9:86-101.

128. Monk BJ, Sill M, Walker J, DiSilvestro P, Sutton G, Tewari KS, Pajon E, Martin L, Schilder J, Coleman R, Balkissoon J, Aghajanian C. Randomized phase II evaluation of bevacizuamb versus bevacizumab/fosbretabulin in recurrent ovarian, tubal, or peritoneal carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 2016;34:2279-86.

129. Monk BJ, Herzog TJ, Tewari KS. Evolution of chemosensitivity and resistance assays as predictors of clinical outcomes in epithelial ovarian cancer patients. Curr Pharm Des 2016;22:4717-28.

130. Longoria TC, Tewari KS. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma. Expert Opin Drug Metab Toxicol 2016; 12:1247-53.

131. Moore KN, Java JJ, Slaughter KN, Rose PG, Lanciano R, DiSilvestro PA, Thigpen JT, Lee YC, Tewari KS, Chino J, Seward SM, Miller DS, Salani R, Moore DH, Stehman FB. Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis. Gynecol Oncol 2016;143:294-301.

132. Garcia-Soto AE, Java JJ, Nieves Neira W, Pearson JM, Cohn DE, Lele SB, Tewari KS, Walker JL, Alvarez Secord A, Armstrong DK, Copeland LJ. Does the time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study. Gynecol Oncol 2016 Oct 7 [Epub ahead of print].

133. Fader AN, Java J, Tenney M, Ricci S, Gunderson CC, Temkin SM, Spirtos N, Kushnir CL, Pearl ML, Zivanovic O, Tewari KS, O’Malley D, Hartenbach EM, Hamilton CA, Gould NS, Mannel RS, Rodgers W, Walker JL. Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis. Gynecol Oncol 2016 Oct 12 [Epubh ahead of print].

134. Minion LE, Tewari KS. The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer. Expert Rev Anticancer Ther 2016 Oct 17 [Epub ahead of print].
135. Rungruang B, Miller A, Krivak TC, Horowitz N, Rodriguez N, Hamilton CA, Backes FJ, Carson L, Friedlander M, Mutch DG, Goodheart MJ, Tewari KS, Wenham RM, Bookman MA, Maxell GL, Richard SD. What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study. Cancer 2016 (in press).

136. Tewari KS. Fifth annual workshop of cytoreductive surgery for advanced ovarian cancer and peritoneal surface malignancies. Gynecol Oncol Res Pract 2016 [Epub ahead of press].
   
Professional
Societies
2017-present Co-Chair – Publications Committee, NRG Onc
2017-present Member, Cervical Cancer Task Force (Nation
2016-present Member, Industry Relations Comm., Society
2016-present Member-at-Large, Nominations Comm., Societ
2014-present Member, Publications Committee, NRG Oncolo
2014-present Institutional Principal Investigator for N
2014-present Chairman, Society of Gynecologic Oncology

   
Other Experience
Graduate Programs Obstetrics and Gynecology

   
   
Link to this profile http://www.faculty.uci.edu/profile.cfm?faculty_id=6112
   
Last updated 01/09/2018